Qompium announces the spin-off of its Extra Horizon business

Hasselt, Oct 3, 2022 - Extra Horizon, a leader in the Medical Backend-as-a-Service (MBaaS) market, has officially demerged from its parent company, Qompium N.V.. For almost a decade now, Qompium has been a leading pioneer in the Software as a Medical Device (SaMD) market with FibriCheck, a device-agnostic mobile application for arrhythmia detection and monitoring.

Extra Horizon is the fully-mature and medical-grade cloud platform that has been the infrastructure foundation of FibriCheck for all these years. It is fully certified and complies with the highest standards in terms of data privacy and security. Since it has been running in production for multiple years already, it can drastically reduce the time to market for new medical innovation startups. This allows startups to bypass the steep learning curve of how to build medical software, and helps them avoid wasting time building core infrastructure blocks. As a result, they can dedicate their time to implementing their business logic instead.

Lars Grieten

“When we started building FibriCheck, we quickly realised that a lot of our time and resources were being invested in making and keeping our product up to date with compliance requirements, scalability needs and offering flexibility. We took the decision to re-invent the way of working and we built a platform, Extra Horizon, that serviced all the needs to support the current and future roadmap of FibriCheck. It quickly became clear that Extra Horizon brings also tremendous value for other companies that aim to develop and commercialise a medical application. By spinning out Extra Horizon, we are proud to see this dream become a reality and that at FibriCheck, we now can maximise the focus of our engineering resources on building value for our end-users.”

This demerger clears the path for both organisations to set their own growth path. Although FibriCheck and Extra Horizon as products are both operating in the medical software space, they are serving different customer bases. 

Whereas FibriCheck directly serves doctors and patients as their end users, both directly and through partnerships and integrations, Extra Horizon will serve other medical software startups, and expects to start operating globally very fast through an international partner network of software studios.

The belief in Extra Horizon’s potential as an independent entity is reflected in the fact that the shareholder structure and the board are now mirrored in both companies. Additionally, the board appoints Hans De Leenheer as its new CEO. Hans, who joined the team a little over a year ago, had already been leading the Extra Horizon business unit as its managing director. Extra Horizon will be looking to secure a seed capital round over the next few months to enable the team to grow its sales and partner network activities.

Hans De Leenheer

“I’ve seen quite a few scale-ups from the inside over the last five years as a strategy advisor. But it’s been very rare for me to find a team and a product with as much potential as Extra Horizon. Without a single exception, everyone on this team specifically joined the company to make a true impact on people’s lives. It will be up to us to create an environment where they can make that happen, and I am extremely honoured for the confidence the team and the board have given me.”